Mellor J, Jiang W, Fleming A, McGurnaghan SJ, Blackbourn L, Styles C, Storkey AJ, McKeigue PM, Colhoun HM, Scottish Diabetes Research Network Epidemiology Group. Can deep learning on retinal images augment known risk factors for cardiovascular disease prediction in diabetes? a prospective cohort study from the national screening programme in Scotland. Int J Med Infrom. 2023 Jul;175:105072. doi: 10.1016/j.ijmedinf.2023.105072
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Glück S, Russell C, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast. 2013 Dec;22(6):1087-93. doi: 10.1016/j.breast.2013.08.016.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.